NASDAQ:JAZZ Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis $123.11 +2.58 (+2.14%) Closing price 04:00 PM EasternExtended Trading$123.20 +0.09 (+0.08%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Jazz Pharmaceuticals alerts:Sign Up Key Stats Today's Range$121.40▼$124.0450-Day Range$105.93▼$123.1152-Week Range$95.49▼$148.06Volume726,062 shsAverage Volume833,761 shsMarket Capitalization$7.47 billionP/E RatioN/ADividend YieldN/APrice Target$181.43Consensus RatingModerate Buy Company Overview Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland. Read More Jazz Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreJAZZ MarketRank™: Jazz Pharmaceuticals scored higher than 90% of companies evaluated by MarketBeat, and ranked 112th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingJazz Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageJazz Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Jazz Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth10.32% Earnings GrowthEarnings for Jazz Pharmaceuticals are expected to grow by 10.32% in the coming year, from $16.96 to $18.71 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jazz Pharmaceuticals is -18.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jazz Pharmaceuticals is -18.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioJazz Pharmaceuticals has a PEG Ratio of 7.60. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioJazz Pharmaceuticals has a P/B Ratio of 2.01. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Jazz Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.46% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 4.36%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJazz Pharmaceuticals does not currently pay a dividend.Dividend GrowthJazz Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.0 / 5Environmental Score-1.96 Percentage of Shares Shorted9.46% of the float of Jazz Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverJazz Pharmaceuticals has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Jazz Pharmaceuticals has recently decreased by 4.36%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.91 News SentimentJazz Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Jazz Pharmaceuticals this week, compared to 15 articles on an average week.Search Interest19 people have searched for JAZZ on MarketBeat in the last 30 days. This is an increase of 90% compared to the previous 30 days.MarketBeat Follows5 people have added Jazz Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Jazz Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $161,580.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Jazz Pharmaceuticals is held by insiders.Percentage Held by Institutions89.14% of the stock of Jazz Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Jazz Pharmaceuticals' insider trading history. Receive JAZZ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address JAZZ Stock News HeadlinesJazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 22 at 4:53 AM | finanznachrichten.deJazz Pharmaceuticals to Participate in the 2025 Wells Fargo Healthcare ConferenceAugust 21 at 4:15 PM | prnewswire.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)Saniona AB: Saniona Enters Exclusive Licensing Agreement with Jazz Pharmaceuticals to Develop and Commercialize SAN2355August 20 at 10:39 PM | finanznachrichten.deJazz Pharmaceuticals enters exclusive licensing deal with SanionaAugust 20 at 10:39 PM | seekingalpha.comJazz Pharmaceuticals to Host Modeyso™ (dordaviprone) Investor Webcast on August 27, 2025August 20 at 4:15 PM | prnewswire.comJazz Pharmaceuticals Enters Exclusive Licensing Agreement with Saniona to Develop and Commercialize SAN2355August 20 at 7:30 AM | prnewswire.comQ2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals StocksAugust 18, 2025 | msn.comSee More Headlines JAZZ Stock Analysis - Frequently Asked Questions How have JAZZ shares performed this year? Jazz Pharmaceuticals' stock was trading at $123.15 on January 1st, 2025. Since then, JAZZ shares have decreased by 0.0% and is now trading at $123.11. How were Jazz Pharmaceuticals' earnings last quarter? Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) announced its quarterly earnings results on Tuesday, August, 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by $2.64. Jazz Pharmaceuticals's quarterly revenue was up 2.1% compared to the same quarter last year. Read the conference call transcript. Does Jazz Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Jazz Pharmaceuticals: Cavion. Who are Jazz Pharmaceuticals' major shareholders? Jazz Pharmaceuticals' top institutional investors include LSV Asset Management (4.22%), State Street Corp (3.19%), Ameriprise Financial Inc. (3.08%) and JPMorgan Chase & Co. (2.84%). Insiders that own company stock include Bruce C Cozadd, Seamus Mulligan, Robert Iannone, Renee D Gala, Neena M Patil, Kim Sablich, Philip L Johnson, Finbar Larkin, Kenneth W O'keefe, Patrick G Enright, Mary Elizabeth Henderson, Samantha Pearce, Rick E Winningham, Patricia Carr, Mark Douglas Smith and Jennifer E Cook. View institutional ownership trends. How do I buy shares of Jazz Pharmaceuticals? Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Jazz Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Jazz Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD), Arista Networks (ANET) and ServiceNow (NOW). Company Calendar Last Earnings8/05/2025Today8/22/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceuticals Current SymbolNASDAQ:JAZZ CIK1232524 Webwww.jazzpharma.com Phone(531) 634-7800Fax353-1634-7850Employees2,800Year Founded2003Price Target and Rating Average Price Target for Jazz Pharmaceuticals$181.43 High Price Target$230.00 Low Price Target$147.00 Potential Upside/Downside+47.0%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($6.73) Trailing P/E RatioN/A Forward P/E Ratio7.28 P/E Growth7.5Net Income$560.12 million Net Margins-9.91% Pretax Margin-12.51% Return on Equity5.02% Return on Assets1.73% Debt Debt-to-Equity Ratio1.17 Current Ratio1.62 Quick Ratio1.37 Sales & Book Value Annual Sales$4.07 billion Price / Sales1.84 Cash Flow$31.49 per share Price / Cash Flow3.92 Book Value$61.10 per share Price / Book2.02Miscellaneous Outstanding Shares60,660,000Free Float58,051,000Market Cap$7.49 billion OptionableOptionable Beta0.34 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:JAZZ) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredUS attacks China, September 30?The White House just ordered more than 400 government agencies to prepare for the next phase of America’s econ...Stansberry Research | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jazz Pharmaceuticals PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Jazz Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.